The effect of glucagon on upper urinary tract peristalsis during extreme diuresis was studied in an unsedated dog preparation. In all experiments glucagon inhibited the peristaltic contraction waves without affecting urine propulsion, suggesting that peristalsis, at least for short periods, is not necessary for effective urine transport during extreme diuresis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0022-5347(17)48818-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Glucagon-like peptide-1 receptor agonists and upper endoscopy: a real-world experience.
Obesity (Silver Spring)
January 2025
Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Objective: Increased use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) has raised safety concerns during endoscopy due to their mechanism of delaying gastric emptying. This study aims to evaluate the impact of GLP-1RAs on technical success and safety of esophagogastroduodenoscopy (EGD).
Methods: This was a retrospective study of bariatric patients who underwent EGD between January 2022 and December 2023.
Summary: An oral contraceptive pill (OCP)-induced increase in total cortisol lead to reversible suppression of the hypothalamic-pituitary-adrenal (HPA) axis and insulin resistance (IR) in a patient with Addison's disease. We suggest that this might influence the choice of an OCP in such patients. A 20-year-old female was diagnosed with Addison's disease (cortisol: 44 nmol/L, adrenocorticotropic hormone (ACTH): >500 pg/mL) and started on hydrocortisone (HC).
View Article and Find Full Text PDFCurrent perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review.
Expert Opin Pharmacother
January 2025
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.
Article Synopsis
- Traditional treatments for obstructive sleep apnea (OSA) mainly focus on methods like continuous positive airway pressure therapy and oral appliances, but they don't tackle the underlying metabolic issues that contribute to the condition.
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially created for managing type 2 diabetes, show promise in helping obese patients with OSA by promoting significant weight loss and reducing fat around the airway.
- Emerging research indicates that integrating GLP-1 RAs into standard OSA treatments could improve patient outcomes by addressing both obesity and related health issues, potentially changing the way OSA is managed in the future.
Remolding probiotics for effective treatment of type 2 diabetes via oral administration.
Biomaterials
April 2025
State Key Laboratory of Food Science and Resources, Nanchang University, Nanchang, 330047, China. Electronic address:
Effective, user-friendly, lifestyle-compatible, and economic treatment for type 2 diabetes (T2D) is urgently needed due to its high incidence and health threats. Here, we remolded Lactococcus lactis through genetic engineering to persistently secrete glucagon-like peptide-1 (L. lactis-GLP-1) and subsequent bioorthogonal arming with dopamine (DA)-based "gripper" and β-glucan (GN)-based "shield" (L.
View Article and Find Full Text PDFIncreased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study.
Expert Opin Drug Saf
November 2024
Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada.
Background: The use of online and/or compounding pharmacies to access glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increases the risk for prescription error (e.g. accidental overdose) especially in racial, ethnic, and socioeconomic disadvantaged groups.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!